vs
Side-by-side financial comparison of Affinity Bancshares, Inc. (AFBI) and NovaBay Pharmaceuticals, Inc. (NBY). Click either name above to swap in a different company.
Affinity Bancshares, Inc. is the larger business by last-quarter revenue ($8.6M vs $4.8M, roughly 1.8× NovaBay Pharmaceuticals, Inc.). Affinity Bancshares, Inc. runs the higher net margin — 24.9% vs -25.5%, a 50.4% gap on every dollar of revenue. On growth, NovaBay Pharmaceuticals, Inc. posted the faster year-over-year revenue change (126.1% vs 12.8%). Affinity Bancshares, Inc. produced more free cash flow last quarter ($11.2M vs $-1.7M). Over the past eight quarters, NovaBay Pharmaceuticals, Inc.'s revenue compounded faster (42.5% CAGR vs 8.1%).
NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis
AFBI vs NBY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $8.6M | $4.8M |
| Net Profit | $2.1M | $-1.2M |
| Gross Margin | — | 65.2% |
| Operating Margin | 35.9% | -37.2% |
| Net Margin | 24.9% | -25.5% |
| Revenue YoY | 12.8% | 126.1% |
| Net Profit YoY | 58.5% | 70.5% |
| EPS (diluted) | $0.34 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.6M | — | ||
| Q3 25 | $8.4M | — | ||
| Q2 25 | $8.3M | — | ||
| Q1 25 | $7.8M | — | ||
| Q4 24 | $7.6M | $4.8M | ||
| Q3 24 | $8.0M | $0 | ||
| Q2 24 | $8.3M | $2.4M | ||
| Q1 24 | $7.3M | $2.6M |
| Q4 25 | $2.1M | — | ||
| Q3 25 | $2.2M | — | ||
| Q2 25 | $2.2M | — | ||
| Q1 25 | $1.8M | — | ||
| Q4 24 | $1.3M | $-1.2M | ||
| Q3 24 | $1.7M | $-1.2M | ||
| Q2 24 | $1.0M | $-1.6M | ||
| Q1 24 | $1.3M | $-3.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 65.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 66.3% | ||
| Q1 24 | — | 68.2% |
| Q4 25 | 35.9% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 34.1% | — | ||
| Q1 25 | 30.8% | — | ||
| Q4 24 | 21.1% | -37.2% | ||
| Q3 24 | 28.5% | — | ||
| Q2 24 | 16.2% | -67.4% | ||
| Q1 24 | 24.0% | -87.1% |
| Q4 25 | 24.9% | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | 25.9% | — | ||
| Q1 25 | 23.4% | — | ||
| Q4 24 | 17.7% | -25.5% | ||
| Q3 24 | 21.7% | — | ||
| Q2 24 | 12.5% | -66.0% | ||
| Q1 24 | 18.2% | -122.2% |
| Q4 25 | $0.34 | — | ||
| Q3 25 | $0.34 | — | ||
| Q2 25 | $0.33 | — | ||
| Q1 25 | $0.28 | — | ||
| Q4 24 | $0.21 | — | ||
| Q3 24 | $0.26 | $-1.92 | ||
| Q2 24 | $0.16 | $-1.37 | ||
| Q1 24 | $0.20 | $-29.95 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.9M | $430.0K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $127.0M | $-129.0K |
| Total Assets | $881.7M | $3.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.9M | — | ||
| Q3 25 | $84.8M | — | ||
| Q2 25 | $89.7M | — | ||
| Q1 25 | $74.7M | — | ||
| Q4 24 | $41.4M | $430.0K | ||
| Q3 24 | $52.3M | $776.0K | ||
| Q2 24 | $50.4M | $751.0K | ||
| Q1 24 | $61.4M | $1.8M |
| Q4 25 | $127.0M | — | ||
| Q3 25 | $125.4M | — | ||
| Q2 25 | $124.1M | — | ||
| Q1 25 | $122.3M | — | ||
| Q4 24 | $129.1M | $-129.0K | ||
| Q3 24 | $128.4M | $1.1M | ||
| Q2 24 | $125.1M | $-617.0K | ||
| Q1 24 | $123.3M | $160.0K |
| Q4 25 | $881.7M | — | ||
| Q3 25 | $925.2M | — | ||
| Q2 25 | $933.8M | — | ||
| Q1 25 | $912.5M | — | ||
| Q4 24 | $866.8M | $3.4M | ||
| Q3 24 | $878.6M | $3.9M | ||
| Q2 24 | $873.6M | $3.9M | ||
| Q1 24 | $869.5M | $5.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $11.6M | $-1.7M |
| Free Cash FlowOCF − Capex | $11.2M | $-1.7M |
| FCF MarginFCF / Revenue | 130.9% | -35.4% |
| Capex IntensityCapex / Revenue | 4.9% | 0.1% |
| Cash ConversionOCF / Net Profit | 5.46× | — |
| TTM Free Cash FlowTrailing 4 quarters | $20.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $11.6M | — | ||
| Q3 25 | $3.7M | — | ||
| Q2 25 | $3.8M | — | ||
| Q1 25 | $1.9M | — | ||
| Q4 24 | $6.8M | $-1.7M | ||
| Q3 24 | $4.1M | $-2.4M | ||
| Q2 24 | $619.0K | $-1.4M | ||
| Q1 24 | $1.2M | $-2.0M |
| Q4 25 | $11.2M | — | ||
| Q3 25 | $3.6M | — | ||
| Q2 25 | $3.7M | — | ||
| Q1 25 | $1.8M | — | ||
| Q4 24 | $6.4M | $-1.7M | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $489.0K | — | ||
| Q1 24 | $1.1M | $-2.0M |
| Q4 25 | 130.9% | — | ||
| Q3 25 | 43.3% | — | ||
| Q2 25 | 44.0% | — | ||
| Q1 25 | 22.7% | — | ||
| Q4 24 | 83.9% | -35.4% | ||
| Q3 24 | 49.5% | — | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 14.8% | -75.3% |
| Q4 25 | 4.9% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 5.6% | 0.1% | ||
| Q3 24 | 1.7% | — | ||
| Q2 24 | 1.6% | 0.0% | ||
| Q1 24 | 1.8% | 0.1% |
| Q4 25 | 5.46× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 1.75× | — | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 5.05× | — | ||
| Q3 24 | 2.36× | — | ||
| Q2 24 | 0.60× | — | ||
| Q1 24 | 0.91× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AFBI
Segment breakdown not available.
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
